Advances in Cardiovascular Science: From Discovery to Translation

Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2024,held from 22nd to 25th July in Chicago, Illinois.

This event features cutting-edge research and advancements in cardiovascular science, including topics like cardiac gene and cell therapy, tissue engineering, and cardiac metabolism.

Attendees will include basic cardiovascular scientists, molecular and cellular biologists, translational investigators, clinical trialists, and practicing cardiologists.

To connect with Dr. Taubel during the event, please reach out to arrange a meeting.

To find out more, click here.

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event